Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KST-6051 in Advanced or Metastatic Solid Tumors With a KRAS Mutation
NCT07458347Phase 1Recruiting
- Sponsor
- Kestrel Therapeutics
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KST-6051 in solid tumor, non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and 1 more (13 arms), sponsored by Kestrel Therapeutics. Primary endpoints: Dose-limiting Toxicities at 3 weeks, Treatment-emergent Adverse Events at 2 years and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
KST-6051
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07458347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07458347.